Free Trial

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences logo
$91.84 +0.19 (+0.21%)
As of 01/17/2025 04:00 PM Eastern

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
11
Buy
16

Based on 27 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 11 have given a hold rating, 13 have given a buy rating, and 3 have given a strong buy rating for GILD.

Consensus Price Target

$97.96
6.66% Upside
According to the 27 analysts' twelve-month price targets for Gilead Sciences, the average price target is $97.96. The highest price target for GILD is $125.00, while the lowest price target for GILD is $69.00. The average price target represents a forecasted upside of 6.66% from the current price of $91.84.
Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

Sign Up

GILD Analyst Ratings Over Time

TypeCurrent Forecast
1/21/24 to 1/20/25
1 Month Ago
12/22/23 to 12/21/24
3 Months Ago
10/23/23 to 10/22/24
1 Year Ago
1/21/23 to 1/21/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
5 Buy rating(s)
Hold
11 Hold rating(s)
12 Hold rating(s)
10 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$97.96$96.43$86.85$86.87
Forecasted Upside6.66% Upside4.17% Upside-1.49% Downside-0.48% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gilead Sciences Stock vs. The Competition

TypeGilead SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.82
2.52
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside6.66% Upside24,741.15% Upside12.44% Upside
News Sentiment Rating
Positive News

See Recent GILD News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/10/2025Morgan Stanley
3 of 5 stars
 UpgradeEqual Weight ➝ Overweight$87.00 ➝ $113.00+26.77%
12/11/2024Cantor Fitzgerald
4 of 5 stars
 Reiterated RatingNeutral ➝ Neutral$80.00 ➝ $80.00-14.61%
12/11/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingSector Perform ➝ Sector Perform$84.00 ➝ $84.00-10.38%
12/10/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$105.00 ➝ $115.00+26.95%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$109.00+20.32%
11/21/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$70.00 ➝ $96.00+6.95%
11/21/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$90.00 ➝ $100.00+12.83%
11/18/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$110.00+19.42%
11/14/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$125.00+34.95%
11/8/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$83.00 ➝ $97.00
11/8/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Okunewitch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
11/7/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$100.00 ➝ $105.00+7.98%
11/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$80.00 ➝ $95.00-2.30%
11/7/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$94.00 ➝ $102.00+4.90%
11/7/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$74.00 ➝ $84.00-13.48%
11/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$84.00 ➝ $95.00-1.72%
11/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$100.00 ➝ $105.00+8.63%
11/7/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$95.00 ➝ $105.00+7.58%
11/7/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
10/21/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/21/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$74.00 ➝ $96.00+10.70%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$105.00+21.04%
8/9/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
U. Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/8/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$93.00+39.45%
4/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$90.00 ➝ $85.00+29.99%
4/24/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold$69.00+2.99%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$75.00-3.72%
2/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$90.00 ➝ $95.00+11.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:58 PM ET.


Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, January 14, 2025. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • Recent analyst upgrades have boosted confidence in Gilead Sciences, Inc., with firms like Oppenheimer raising their price target to $115.00, indicating strong potential for growth.
  • The current stock price is approximately $91.39, which may present a buying opportunity for investors looking to enter at a favorable valuation.
  • Gilead Sciences, Inc. has a diverse portfolio of biopharmaceutical products addressing unmet medical needs, which can lead to sustained revenue growth.
  • Insider selling has been relatively modest, with insiders owning only 0.16% of the company, suggesting that there may not be significant concerns about the company's future performance.
  • The company has received a consensus rating of "Moderate Buy" from analysts, reflecting overall positive sentiment in the market.

Gilead Sciences
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • Insider sales totaled 455,734 shares valued at over $42 million in the last ninety days, which could signal a lack of confidence among executives regarding the stock's future performance.
  • Despite recent upgrades, the stock has faced volatility, which may deter risk-averse investors looking for stable investments.
  • With twelve analysts rating the stock as a hold, there may be concerns about the company's ability to outperform the market in the near term.
  • Gilead Sciences, Inc. operates in a highly competitive biopharmaceutical industry, which can impact its market share and profitability.
  • The company's relatively low insider ownership (0.16%) may indicate a lack of alignment between management and shareholder interests.

GILD Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $97.96, with a high forecast of $125.00 and a low forecast of $69.00.

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 11 hold ratings, 13 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GILD shares.

According to analysts, Gilead Sciences's stock has a predicted upside of 6.66% based on their 12-month stock forecasts.

Over the previous 90 days, Gilead Sciences's stock had 3 upgrades and 1 downgrade by analysts.

Analysts like Gilead Sciences less than other "medical" companies. The consensus rating score for Gilead Sciences is 2.70 while the average consensus rating score for "medical" companies is 2.82. Learn more on how GILD compares to other companies.


This page (NASDAQ:GILD) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners